Abstract
The activated partial thromboplastin time after heparin removal (aPTT/HR) is an anionexchange procedure that permits the unobstructed monitoring of the progress of coumarin anticoagulation by removing interfering heparin. An all-intrinsic-pathway anticoagulant surveillance scheme based upon the aPTT/HR has been proposed and provisionally tested. The adoption of the new scheme will depend upon the identification of partial thromboplastins that are as predictable and reliable as the tissue thromboplastins in modern one-stage prothrombin times. In this study, the commercial APTT Reagent and Simplastin performed with equal sensitivity and specificity when evaluated by means of prothrombin group factor assays on coumarintreated subject plasmas. It is concluded that this commercial partial thromboplastin (1) is capable of being used for the purpose of following heparin, heparin plus coumarin, and coumarin anticoagulation; (2) is potentially able to identify more of the inherited and acquired derangements that can lead to anticoagulation-associated hemorrhage; and (3) is a universally available alternative to the traditional anticoagulant monitoring approach.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Basu D., Gallus A., Hirsh J., Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med. 1972 Aug 17;287(7):324–327. doi: 10.1056/NEJM197208172870703. [DOI] [PubMed] [Google Scholar]
- Branson H. E., Gupta N., Slater L. M., Fagin A., Armentrout S. A. Activated partial thromboplastin time after heparin removal (aPTT/HR) in a new scheme of anticoagulant monitoring. Am J Hematol. 1982 Jun;12(4):411–418. doi: 10.1002/ajh.2830120413. [DOI] [PubMed] [Google Scholar]
- Branson H. E., Slater L. M., Anderson M. G., Pirkle H. Prothrombin time after heparin removal. Application to monitoring simultaneous anticoagulation with heparin and coumarins. Am J Clin Pathol. 1979 Jun;71(6):665–667. doi: 10.1093/ajcp/71.6.665. [DOI] [PubMed] [Google Scholar]
- Gomperts E. D., Zucker M. L. Heparin, brain thromboplastin and the insensitivity of the prothrombin time to heparin activity. Thromb Res. 1978 Jan;12(1):105–117. doi: 10.1016/0049-3848(78)90089-0. [DOI] [PubMed] [Google Scholar]
- OWREN P. A., AAS K. The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand J Clin Lab Invest. 1951;3(3):201–208. doi: 10.3109/00365515109060600. [DOI] [PubMed] [Google Scholar]
- OWREN P. A. Thrombotest. A new method for controlling anticoagulant therapy. Lancet. 1959 Nov 7;2(7106):754–758. doi: 10.1016/s0140-6736(59)90857-8. [DOI] [PubMed] [Google Scholar]